Drug intelligence / Profile preview

HGS1025

Development stage: Discontinued
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

HGS1025 is a human monoclonal antibody that targets the C-C chemokine receptor type 5 (CCR5). It was developed as an antagonist of CCR5, aiming to block this receptor's activity. The drug was investigated for use in immune-mediated diseases, specifically ulcerative colitis. Its mechanism involves antagonism of CCR5, which plays a role in immune cell trafficking and inflammation. The development reached Phase 1b clinical trials for ulcerative colitis but was withdrawn before completion and has not been approved or marketed[1][2][3][4].

Other names: Anti-CCR5 monoclonal antibodyAnti-CCR-5 monoclonal antibodyAnti-CCR 5 monoclonal antibody

Targets

CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on HGS1025.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HGS1025.

Explore the full profile